Evaluation of a new alpha-blocking vasodilator agent (thymoxamine) in peripheral vascular disease.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy; D005260:Female; D005528:Foot / Q000098:blood supply; D006225:Hand / Q000098:blood supply; D006801:Humans; D006873:Hydroquinones / Q000009:adverse effects / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010991:Plethysmography; D011928:Raynaud Disease / Q000601:surgery; D012039:Regional Blood Flow / Q000187:drug effects; D013562:Sympathectomy; D013565:Sympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D006873:Hydroquinones; D013565:Sympatholytics; D014665:Vasodilator Agents